Literature DB >> 12959220

Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.

Salvador Resino1, Isabel Galán, José M Bellón, M Luisa Navarro, Juan Antonio León, M Angeles Muñoz-Fernandez.   

Abstract

Thirty two HIV-infected children, on highly active antiretroviral therapy (HAART) and > 500 CD4+ T cells/mm3, were rated according to the time-course of viral load (VL) during the whole follow-up period (> 18 months) in a longitudinal retrospective study. (a) uVL group: 15 children with VL below 400 copies/mL; (b) dVL group: 17 children with higher VL. The uVL group showed higher memory (CD4+CD45RO+) T cells than did dVL group, and higher number of memory activated CD4+CD45RO+HLA-DR+ than did control group (healthy age-matched uninfected children), whereas CD4+CD45RA(hi)+CD62L+ was similar. However, TCR rearrangement excision circles (TRECs) were higher in uVL group than in dVL group. uVL Group showed CD8+CD45RO+ and CD8+CD45RO+CD38- higher number than the control group, but lower than the dVL group. The percentage of CD8+CD45RA(hi)+CD62L+, CD8+CD45RA+, CD8+CD62L-, and CD8+CD28+ was higher in uVL group than in dVL group, and lower than in control group. The uVL group showed higher number of activated (HLA-DR+CD38+, HLA-DR+, HLA-DR+CD38-) CD4+ T cells and lower percentages of CD4+HLA-DR-CD38+ than dVL group. In activated CD8- T cell, the uVL group had lower CD8+HLA-DR+CD38+, CD8+HLA-DR+, and CD8+CD38+ than the dVL group. Preeffector (CD8+CD57-CD28- and CD8+CD45RA-CD62L-) T cells were lower in the uVL group than in dVL group. In the effector (CD8+CD57+, CD8+CD57+CD28-, and CD8+CD45RA+CD62L-) T cells, HIV-infected-children had higher values than control group. HIV-infected-children who respond to HAART had TRECs reconstitution, decreased immune activation, and lower effector CD8+ T cells. Moreover, successful HAART allow the increment of activated CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959220     DOI: 10.1023/a:1024536816684

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  73 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Dynamics of T cell responses in HIV infection.

Authors:  Victor Appay; Laura Papagno; Celsa A Spina; Pokrath Hansasuta; Abigail King; Louise Jones; Graham S Ogg; Susan Little; Andrew J McMichael; Douglas D Richman; Sarah L Rowland-Jones
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

3.  Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-04-17

4.  Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.

Authors:  M A Muñoz-Fernández; E Obregón; J Navarro; C Börner; M D Gurbindo; T H Sampelayo; E Fernández-Cruz
Journal:  Pediatr Res       Date:  1996-10       Impact factor: 3.756

5.  CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients.

Authors:  A Mocroft; M Bofill; M Lipman; E Medina; N Borthwick; A Timms; L Batista; M Winter; C A Sabin; M Johnson; C A Lee; A Phillips; G Janossy
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

6.  Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.

Authors:  A Vigano; S Vella; M Saresella; A Vanzulli; D Bricalli; S Di Fabio; P Ferrante; M Andreotti; M Pirillo; L G Dally; M Clerici; N Principi
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

7.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

8.  Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations.

Authors:  J E Brinchmann; J H Dobloug; B H Heger; L L Haaheim; M Sannes; T Egeland
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

9.  Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.

Authors:  M L Gougeon; H Lecoeur; A Dulioust; M G Enouf; M Crouvoiser; C Goujard; T Debord; L Montagnier
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

10.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  10 in total

1.  HIV-1 seronegativity in a child with proved perinatal HIV infection on HAART.

Authors:  N Desai; M Mathur; K Abu-Lawi
Journal:  Sex Transm Infect       Date:  2005-10       Impact factor: 3.519

2.  Immunologic basis for revaccination of HIV-infected children receiving HAART.

Authors:  Kaitlin Rainwater-Lovett; William J Moss
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

3.  The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda.

Authors:  Isaac Ssewanyana; Chris A R Baker; Theodore Ruel; Stephanie Bousheri; Moses Kamya; Grant Dorsey; Philip J Rosenthal; Edwin Charlebois; Diane Havlir; Huyen Cao
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

4.  Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.

Authors:  A Anselmi; D Vendrame; O Rampon; C Giaquinto; M Zanchetta; A De Rossi
Journal:  Clin Exp Immunol       Date:  2007-10-22       Impact factor: 4.330

5.  Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.

Authors:  Li Yin; Carina A Rodriguez; Wei Hou; Olivia Potter; Margaret J Caplan; Maureen M Goodenow; John W Sleasman
Journal:  J Allergy Clin Immunol       Date:  2008-06-09       Impact factor: 10.793

6.  Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study.

Authors:  Oluwaseun Falade-Nwulia; Eric C Seaberg; Anna E Snider; Charles R Rinaldo; John Phair; Mallory D Witt; Chloe L Thio
Journal:  Ann Intern Med       Date:  2015-10-13       Impact factor: 25.391

7.  Changes in cellular immune activation and memory T-cell subsets in HIV-infected Zambian children receiving HAART.

Authors:  Kaitlin Rainwater-Lovett; Hope Nkamba; Mwangelwa Mubiana-Mbewe; Carolyn B Moore; Joseph Margolick; William J Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

8.  Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.

Authors:  Salvador Resino; Elena Seoane; Alicia Pérez; Ezequiel Ruiz-Mateos; Manuel Leal; Maria A Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2006-07-13       Impact factor: 3.090

9.  Profiling of Inflammatory Proteins in Plasma of HIV-1-Infected Children Receiving Antiretroviral Therapy.

Authors:  Mahlet Lemma; Stefan Petkov; Yonas Bekele; Beyene Petros; Rawleigh Howe; Francesca Chiodi
Journal:  Proteomes       Date:  2020-09-07

10.  Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?

Authors:  Yonas Bekele; Rebecka Lantto Graham; Sandra Soeria-Atmadja; Aikaterini Nasi; Maurizio Zazzi; Ilaria Vicenti; Lars Naver; Anna Nilsson; Francesca Chiodi
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.